Investigational New Drugs

, Volume 20, Issue 1, pp 123–127

A Phase II Trial of Bryostatin-1 in Patients with Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck

  • David G. Pfister
  • John McCaffrey
  • Andrew J. Zahalsky
  • Gary K. Schwartz
  • Eric Lis
  • William Gerald
  • Andrew Huvos
  • Jatin Shah
  • Dennis Kraus
  • Ashok Shaha
  • Bhuvanesh Singh
  • Suzanne Wolden
  • Michael Zelefsky
  • Ilana Palgi
Article

DOI: 10.1023/A:1014449309165

Cite this article as:
Pfister, D.G., McCaffrey, J., Zahalsky, A.J. et al. Invest New Drugs (2002) 20: 123. doi:10.1023/A:1014449309165

Abstract

Bryostatin-1 is a macrocyclic lactone thathas been shown to modulate Protein Kinase Cactivity and has demonstrated antitumoractivity in vitro and in vivo. Fifteen patients with metastatic orrecurrent squamous cell carcinoma of thehead and neck were treated withbryostatin-1 at a dose of 25 mcg/m2 bycontinuous intravenous infusion over 24hours once weekly for three weeks followedby a break week to complete a four-weekcycle. There were no major objectiveresponses in the 14 evaluable patients. One patient with nasopharynx cancer haddisease stabilization for 4 months prior tobeing removed from the study due to medicalissues. This clinical benefit correspondedto a radiographic decrease in metabolicactivity on positron emission tomograpy(PET) scan as well as molecular evidence oftumor apoptosis in a poly[ADP-ribose]polymerase (PARP) cleavage assay. Bryostatin-1 is not recommended for use asa single agent for the treatment ofsquamous cell head and neck cancer. Further investigation is warranted todetermine the strength of the correlationbetween bryostatin-1 activity and PARPcleavage as a surrogate molecular marker ofapoptosis.

bryostatin-1head and neck cancer

Copyright information

© Kluwer Academic Publishers 2002

Authors and Affiliations

  • David G. Pfister
    • 1
  • John McCaffrey
    • 1
  • Andrew J. Zahalsky
    • 1
  • Gary K. Schwartz
    • 1
  • Eric Lis
    • 2
  • William Gerald
    • 2
  • Andrew Huvos
    • 2
  • Jatin Shah
    • 3
  • Dennis Kraus
    • 3
  • Ashok Shaha
    • 3
  • Bhuvanesh Singh
    • 3
  • Suzanne Wolden
    • 4
    • 5
  • Michael Zelefsky
    • 4
    • 5
  • Ilana Palgi
    • 1
  1. 1.Division of Solid Tumor Oncology, Department of MedicineMemorial Sloan-Kettering Cancer CenterUSA
  2. 2.Department of RadiologyMemorial Sloan-Kettering Cancer CenterUSA
  3. 3.Head and Neck Surgery Service, Department of SurgeryMemorial Sloan-Kettering Cancer CenterUSA
  4. 4.Department of Radiation OncologyMemorial Sloan-Kettering Cancer CenterUSA
  5. 5.Departments of Medicine, Radiology, Pathology, and SurgeryCornell University Medical CollegeNew YorkUSA